Keywords: lilly, arzoxifene, superior, 1b-a-year, evista, ph, iii

Lilly's arzoxifene superior to $1.1B-a-year Evista in Ph III osteoporosis study

Article | 30 March 2009

Print This

US drug major Eli Lilly has presented Phase III data showing that its drug candidate arzoxifene was superior to its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in